Kennyjo
4 주 전
Zentek and Triera Biosciences Ltd. Receive $1.1 Million Government of Canada Contract to Test Multivalent Aptamer Technology
Guelph, ON – November 6, 2024, Zentek Ltd. (“Zentek” or the “Company”) (Nasdaq: ZTEK; TSX-V: ZEN), announces that its wholly-owned subsidiary Triera Biosciences Ltd. (“Triera”) has received a $1.1 million Government of Canada contract to test its multivalent aptamer technology for the rapid drug discovery of therapeutics or prophylactics of highly pathogenic avian influenza (“HPAI”) A(H5N1).
Highlights:
The Government of Canada has identified the life sciences sector as a priority of the Canadian economy and is seeking advanced medical technology solutions to address ongoing challenges
Triera was awarded a $1.1 million Government of Canada R&D contract through Innovation, Science and Economic Development Canada's (“ISED”) Innovative Solutions Canada (“ISC”) program: Health Advanced And Emerging Medical Technologies
Triera’s multivalent aptamer technology was selected for its potential to be used as a rapid drug development platform
Government of Canada testing partners include Health Emergency Readiness Canada (“HERC”) within ISED and Defence Research and Development Canada (“DRDC”), the science and technology organization of the Department of National Defence (“DND”)
The test will help develop a prophylactic and therapeutic for HPAI A(H5N1) following the multivalent aptamer strategy that successfully produced a SARS-CoV-2 aptamer
Triera has proven the capability of the multivalent aptamer platform by developing a universal therapeutic and prophylactic that is effective against all variants of SARS-CoV-2. The contract will allow Triera to prove the capability for developing a lead candidate for HPAI A(H5N1).
HERC is a new federal organization within ISED dedicated to protecting Canadians against future pandemics and delivering on Canada’s life sciences and medical countermeasures readiness objectives. HERC will provide a sustained focus on advancing life sciences industrial capabilities and innovation to respond to health threats, building on significant achievements in the sector since 2020, including $2.2B that has been invested under Canada’s Biomanufacturing and Life Sciences Strategy.
DRDC is Canada's defence science, technology, and innovation leader. DRDC develops and delivers new technical solutions and advice to the DND, the Canadian Armed Forces, and safety and security communities. This is accomplished by working with partners in industry, academia, other government departments and international allies.
The contract requires Triera to develop a lead candidate for HPAI A(H5N1) within six months of the project initiation. The lead candidate will be tested for its efficacy as a therapeutic and prophylactic along with its safety profile by the Miller Laboratory at McMaster University.
“We are very pleased that our multivalent aptamer platform has been recognized through this ISC Program Testing Stream. We are working with government organizations that understand the significance of our avian flu program and can promote and support further development of our technology. Upon successful completion, Triera will be eligible for further government investment and recognition from Canada and its key allies,” said Greg Fenton, CEO of the Company and Triera.
“The potential for an avian influenza pandemic continues to grow and the consequences of a new variant, which would allow human-to-human transmission, could lead to devastating results,” Triera’s advisor, Dr. Matthew Miller said, “As with national security, the need for an outbreak response must be regarded as a failure to prevent.”
About Triera Biosciences Ltd.
Triera holds an exclusive, worldwide royalty bearing license from McMaster University to use and practice all aptamer and DNAzyme uses developed through the collaboration with the Li Lab by McMaster University for the next 20 years. Triera and McMaster’s combined expertise and capabilities in aptamer technology offer significant potential to reduce the cost and time required for the development of new treatments.
Kennyjo
1 월 전
Zentek Provides Regulatory Update for
ZenGUARD™ Enhanced Air Filters
Guelph, ON – October 31, 2024, Zentek Ltd. (“Zentek” or the “Company”) (Nasdaq: ZTEK; TSX-V: ZEN), an intellectual property development and commercialization company announces that it has withdrawn its submission to the Health Canada Pest Management Regulatory Agency (“PMRA”) for its ZenGUARD™ Enhanced Air Filters. Based on feedback received from PMRA, and continued analysis of the Canadian regulatory environment, the Company believes there are other, more cost-effective, and timely pathways, to bring ZenGUARD™ Enhanced Air Filters to market in Canada. The Company has been evaluating and planning for these potential alternative options in parallel with the PMRA assessment process over the last several months and will now shift its focus to these other pathways.
“Our top priority as a Company is ensuring we do everything we can to create value for our stakeholders as quickly and effectively as possible, which is why we are shifting our focus to pursue other pathways to market in Canada for ZenGUARD™ Enhanced Air Filters,” said Greg Fenton, CEO of Zentek.
“Importantly, we know that one of the biggest challenges facing society is climate change and building decarbonization. Buildings contribute nearly 40% of global energy-related CO2 emissions – and ZenGUARD™ Enhanced Air Filters are one of the only tools in the toolbox to help control infectious aerosols without significantly increasing energy consumption and emissions. The sooner we can bring ZenGUARD™ Enhanced Air Filters to market, the sooner we can do our part to help reduce emissions while keeping people safe indoors – not only in Canada, but globally as well.”
Kennyjo
2 월 전
Zentek Provides Market Update on ZenGUARD™ Antimicrobial Surgical Masks
Guelph, ON – October 17, 2024, Zentek Ltd. (“Zentek” or the “Company”) (Nasdaq: ZTEK; TSX-V: ZEN), an intellectual property development and commercialization company, is pleased to provide an update on recent commercialization activities for its ZenGUARD™ Antimicrobial Surgical Masks.
As previously announced on July 24, 2024, the Company embarked on a Canada-wide sampling program for dental professionals facilitated by Henry Schein Inc. (“Henry Schein") that saw ZenGUARD™ Antimicrobial Surgical Masks included in product shipments to Henry Schein customers across Canada. As a result of this program and the unique value proposition ZenGUARD™ Antimicrobial Surgical Masks bring to dental practitioners and their patients, the Company is now seeing increased demand from Henry Schein. Henry Schein (Nasdaq: HSIC) is the world’s largest provider of health care solutions to office-based dental and medical practitioners with a presence in 33 countries.
Zentek continues to explore opportunities in other markets including in the beauty space and in international healthcare and dental markets where demand for surgical masks is expected to be more stable long term.
As previously announced on April 24, 2024, the Company applied to the Food and Drug Administration (FDA) for authorization to market and sell its ZenGUARD™ Surgical Masks in the United States. The FDA has requested additional information regarding ZenGUARD™ and the Company is currently evaluating the additional information requests.
“In addition to better protection against infectious agents, ZenGUARD™ Antimicrobial Surgical Masks are also proven to eliminate 99.9% of bacteria, which can collect on the skin when wearing a surgical mask for extended periods and cause acne. We believe this unique value proposition will continue to drive increased demand in the dental market and is a very natural fit for the beauty industry as well. We look forward to continuing to build on the recent success generated in the Henry Schein sampling program and to expanding the platform globally.” said Greg Fenton, Zentek CEO.
Kennyjo
1 년 전
Zentek Announces Distribution and Supply Agreement with Henry Schein, Inc.
Guelph, ON
August 24, 2023
Zentek Ltd. (“Zentek” or the “Company”) (Nasdaq: ZTEK; TSX-V: ZEN), a graphene technology development and commercialization company has signed a Distribution and Supply Agreement with Henry Schein, Inc. (Henry Schein). This initial agreement will be for a period of three years and is for Canada and the United States. Sales of ZenGUARD™ surgical masks in the United States will commence upon facility establishment registration and issuance of market clearance from the Food and Drug Administration.
Henry Schein is the world’s largest provider of health care solutions to office-based dental and medical practitioners. The Henry Schein team will market and distribute ZenGUARD™ surgical masks to dental practices in the U.S. and Canada.
Greg Fenton, CEO of Zentek commented: “Henry Schein has been a leading company in the sales and distribution of health care products for over 90 years and been recognized by FORTUNE® as one of the World’s Most Admired Companies. We are proud to have our ZenGUARD™ surgical masks carried by one of the most respected distributors in the world. We believe this is another meaningful step toward securing volumes in a market segment with stable demand for surgical masks. While our focus is currently on surgical masks in Canada, we look forward to exploring other opportunities for our ZenGUARD™ platform in the dental space with Henry Schein.”
About Zentek Ltd.
Zentek is an ISO 13485:2016 certified graphene technology company focused on the research, development and commercialization of graphene-based novel products seeking to give the Company's commercial partners a competitive advantage by making their products better, safer, and greener.
Zentek's patented technology platform ZenGUARD™, is shown to have 99% antimicrobial activity and to significantly increase the bacterial and viral filtration efficiency of both surgical masks and HVAC (heating, ventilation, and air conditioning) systems. Zentek's ZenGUARD™ production facility is located in Guelph, Ontario. Zentek's patent pending ZenARMOR™ technology platform is focused on corrosion protection applications.
For further information:
Investorrelations@zentek.com
Kennyjo
2 년 전
More news
Zentek Files Patent Applications for ZenGUARD™ in Multiple New Jurisdictions
Guelph, ON
April 5, 2023
Zentek Ltd. (“Zentek” or the “Company”) (Nasdaq: ZTEK; TSX-V: ZEN), a graphene technology development and commercialization company, has filed patent applications for ZenGUARD™ in 47 countries.
The examiner for the Patent Cooperation Treaty, the international patent law treaty, that reviewed the ZenGUARD™ patent application opined that it met all 3 requirements to be granted a patent: novelty, an inventive step and industrial applicability. The Company has also been granted a patent for ZenGUARD™ by the Canadian Intellectual Property Office, as previously announced on December 7th, 2022. Examiners in other jurisdictions will use these actions as a basis for their own examinations and granting of patents in their respective countries.
The patented ZenGUARD™ antimicrobial technology platform has demonstrated it is a powerful solution for deactivating pathogens and increasing bacterial and viral filtration efficiency of both surgical masks and HVAC filters.
Based on the above information, the Company has decided to file patents in 47 new jurisdictions, including the United States, Europe, India and others and expects to be successful in all of them. The patent covers the chemical formula for ZenGUARD™, a fabrication method along with its application to various substrates, including surgical mask material, other personal protective equipment (PPE) and heating, ventilation, and air conditioning (HVAC) filters.
“We expect our patented ZenGUARD™ antimicrobial platform can provide numerous opportunities to give our business partners a competitive advantage in their respective markets, which we believe will make it a cornerstone for Zentek,” commented Greg Fenton, CEO of Zentek. He continued, “Importantly, this demonstrates our ability to move from a concept in the lab to a patent-protected technology platform that we hope to commercialize in numerous ways with several partners – all with the aim of making their products better, safer, and greener. We expect to follow a similar path for our other nanotechnologies, including ZenARMOR™, our patent-pending corrosion technology, and others.”
Kennyjo
2 년 전
Update
Zentek NEWS
Zentek Engages Arka BRENStech Pvt Ltd to Develop Opportunities in India
Guelph, ON
March 30, 2023
Zentek Ltd. (“Zentek” or the “Company”) (Nasdaq: ZTEK; TSX-V: ZEN), an intellectual property development and commercialization company, has signed an agreement (the “Agreement”) with Arka BRENStech Pvt Ltd (“BRENStech”), a company incorporated under the laws of the Republic of India (India), pursuant to which BRENStech will act as a local partner to Zentek as it seeks to develop business opportunities in India.
Zentek has been working with Mr. Gaurav Kumar, a director of BRENStech, over the last year to understand the Indian market. BRENStech’s primary focus under the terms of the Agreement will be to establish sales and distribution opportunities for Zentek masks and HVAC filters and potentially other Zentek products as they become available, however BRENStech will also provide services under the Agreement to connect Zentek with university research facilities, assist with the navigation of applicable regulatory regimes, and to source potential manufacturing partners for Zentek’s business opportunities in India and globally.
To date, BRENStech has performed market research of the Indian market for surgical masks where samples were trialed in hospitals and clinics and has reported positive feedback and Zentek has shipped 2.1 million masks to support initial sales efforts. The personal protective equipment (“PPE”) market in India is valued at $1 billion USD and India is currently the world’s second largest manufacturer of PPE according to the Economic Times, India.
“We see significant opportunities in India, both as a market for Zentek’s innovative products and as a potential manufacturing hub for Zentek going forward” said Greg Fenton, CEO of Zentek. “Having a strong partner in India with business, research and development, regulatory and political connections will be invaluable as we seek to grow our opportunities both in India and globally.”
Currently, India is the world’s 5th largest economy and expected to grow to the 3rd largest by 2030 according to the International Monetary Fund. India is projected to host over 1.5 billion people by 2030 making it the highest population in the world. Currently the estimated middle class has approximately 350 million people and targeted to reach 600 million by 2030. India offers significant opportunities for Zentek and its partners: Sales and distribution, strong manufacturing infrastructure along with world-class research and development.
About Zentek Ltd.
Zentek is an IP development and commercialization company focused on the research, development and commercialization of novel products using graphene and nanomaterials for use in the healthcare industry and beyond.
Zentek’s patented ZenGUARD™ coating is shown to have 99% antimicrobial activity and to significantly increase the bacterial and viral filtration efficiency of both surgical masks and HVAC systems. Zentek's ZenGUARD™ production facility is located in Guelph, Ontario.
About Arka BRENStech Pvt Ltd.
BRENStech is a leading consulting company that is focused on technology and has a history of developing and deploying cutting-edge technologies. The company works primarily in the realm of environmental sustainability and renewable energy but is also well diversified and active in many other areas of industry and is well positioned for companies entering India under joint ventures.
BRENStech has been in business for over 10 years and has corporate offices in Gurugram (on the outskirts of New Delhi), Hyderabad, Bangalore, and Chandigarh which provide a presence throughout India. The company also has an extensive network established in the private and public sectors as it works with a wide range of SMEs as well as large multinationals. The company maintains a close working relationship with numerous departments and agencies throughout all levels of Government and participates actively in policy formation. BRENStech offers its partners a strong combination of technical expertise and business knowledge to help bring emerging technologies to market.
For further information:
Mitch Swergold
Tel: (917) 930-8723
Email: mswergold@zentek.com
To find out more about Zentek Ltd., please visit our website at www.Zentek.com. A copy of this news release and all material documents in respect of the Company may be obtained on ZEN’s SEDAR profile at http://www.sedar.com/.
Forward-Looking Statements
This news release contains forward-looking statements. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Although Zentek believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Zentek disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Zentek on Facebook!
Zentek on Twitter!
Zentek on Instagram!
Zentek's Website
Zentek on LinkedIn!
Copyright © 2023 Zentek Ltd., All rights reserved.
You are receiving this email because you opted in via our website.
Our mailing address is:
Zentek Ltd.
210-1205 Amber Drive
Thunder Bay, ON P7B6M4
Canada
Add us to your address book
Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list.
Email Marketing Powered by Mailchimp
Kennyjo
2 년 전
How about this ?
Guelph, ON
March 22, 2023
Zentek Ltd. (“Zentek” or the “Company”) (Nasdaq: ZTEK; TSX-V: ZEN), an intellectual property development and commercialization company, announces that SGS Standard Technical Services Co. (“SGS”) recently conducted tests to determine the extent of the antimicrobial properties and the time required to achieve deactivation of bacteria and virus on ZenGUARD™-coated mask material.
“Our goal at Zentek from early on in the pandemic was to create a technology that could improve the health and safety of our valued frontline healthcare workers” said Greg Fenton, CEO of Zentek. “Our patented ZenGUARD™ antimicrobial technology with 99.99% bacterial and viral filtration efficiency brings an added level of protection that doctors, nurses and all frontline healthcare providers deserve. We are excited to bring our unique ZenGUARD™ surgical masks to them via our Canadian distribution partnership with Southmedic Inc.”
Key Data points
Antibacterial testing completed by SGS following AATCC 100-2019 Test
Method for Antibacterial Finishes on Textile Material
Antiviral testing completed by SGS and followed ISO 18184: 2019 Textiles – Determination of antiviral activity of textile products TCID50 method
The ZenGUARD™-coated mask fabric demonstrated over 99.99% antibacterial effectiveness after 1 hour where 260,000 Escherichia Coli (E. coli) Colony Forming Units (CFU) was reduced to under 100 CFU.
The untreated control mask samples saw 120,000 E. coli CFU grow to 2.5 million in 1 hour and 1.1 billion in 8 hours
The ZenGUARD™-coated mask fabric demonstrated 86.7% antiviral effectiveness after 1 hour against H1N1 and 99.7% after 8 hours
These meaningful reductions in bacterial and viral load may have an impact in the reduction of infectious disease in high-risk environments
Impact in High-Risk Environments
In the context of high-risk indoor settings, such as hospitals where doctors, nurses and other healthcare professionals and patients wear surgical masks and are exposed to dangerous bacteria and viruses daily, this data offers compelling evidence that ZenGUARD™-coated mask material can provide additional protection with the strong antimicrobial properties of ZenGUARD™. The reduction in bacterial and viral growth in the mask materials may contribute to protecting doctors, nurses, other hospital staff and patients, as well as long term care residents and their caretakers, from mask acne to potentially preventing significant disease from bacterial or viral infections.
Southmedic Inc. is Zentek's exclusive distribution partner in Canada for hospitals, clinics, long-term care, nursing homes and community health care services. For any purchase requirements, please contact Southmedic Customer Service at custserv@southmedic.com or by phone at 1-800-463-7146, Mon - Fri 8:30am - 5:00pm.
About Zentek
Zentek is an IP development and commercialization company focused on the research, development and commercialization of novel products using graphene and nanomaterials for use in the healthcare industry and beyond.
Zentek’s patented ZenGUARD™ coating is shown to have 99% antimicrobial activity and to significantly increase the bacterial and viral filtration efficiency of both surgical masks and HVAC systems. Zentek's ZenGUARD™ production facility is located in Guelph, Ontario.
For further information:
Mitch Swergold
Tel: (917) 930-8723
Email: mswergold@zentek.com
To find out more about
Kennyjo
2 년 전
Zentek’s ZenGUARD™ Patent Application Allowed by the Canadian Patent Office
Guelph, ON
September 27, 2022
Zentek Ltd. (“Zentek” or the “Company”) (Nasdaq: ZTEK; TSX-V: ZEN), an intellectual property (IP) development and commercialization company, is pleased to announce that on September 16, 2022, it’s Canadian patent application directed to its ZenGUARD™ technology, for use on personal protective equipment (“PPE”), and heating, ventilation, and air conditioning (“HVAC”), has been allowed by the Canadian Intellectual Property Office including all 54 claims made in the application. Zentek is now working with its IP counsel to map out the strategy to extend patent protection of its commercial rights in all global jurisdictions of interest.
“This is tremendous news for our company and shareholders,” said Greg Fenton, CEO for Zentek. “Our team has worked diligently with our patent attorneys to map out a strong strategy to protect ZenGUARD™ and our other graphene-based technologies. By moving this technology from the lab all the way through to a patent and commercialization, this milestone validates the Zentek business model of being an intellectual property development and commercialization company. In two short years we have taken this game changing technology for the fight against Covid-19 and other airborne pathogens from a concept to a fully protected asset of the company.”
Kennyjo
2 년 전
September 20, 2022
Zentek Ltd. (“Zentek” or the “Company”) (Nasdaq: ZTEK; TSX-V: ZEN), an intellectual property development and commercialization company, announces that Greg Fenton, CEO, will hold investor meetings and present at this year’s Sidoti Small-Cap Virtual Investor Conference, which will be held September 21-22, 2022.
Mr. Fenton will deliver his corporate presentation on Thursday, September 22nd at 12:15PM ET, and can be accessed live here: https://sidoti.zoom.us/webinar/register/WN_JpxPXpukRwSFbGSx-di-BA
The Sidoti Small Cap Conference is a virtual event featuring dynamic, small-cap companies interacting with top institutional investors. Sidoti is a provider of independent securities research focused on small and micro-cap companies and the institutions that invest their securities. Their investor conferences have emerged as a leading forum for interaction between issuers and investors in the small and micro-cap investment community.
“The value proposition for Zentek is tremendous as our company continues to advance its IP pipeline and commercialization opportunities in a number of areas, most notably with ZenGUARD™ in the personal protective equipment and indoor air filtration markets,” said Greg Fenton, CEO. “We’re in good company at this year’s conference and look forward to reinforcing our unique value proposition with US investors.”
For more information, and to register, visit https://www.sidoti.com/events/fall-small-cap-virtual-conference.
About Zentek Ltd.
Zentek is an IP development and commercialization company focused on the research, development and commercialization of novel products using graphene and nanomaterials for use in the healthcare industry and beyond.
Zentek’s proprietary ZenGUARD™ coating is patent-pending and shown to have 99% antimicrobial activity, including against COVID-19, for use in PPE and potentially HVAC systems and other industries. Zentek's ZenGUARD™ production facility is located in Guelph, Ontario.
For further information:
Tyler Dunn
Tel: (306)717-6745
Email: tdunn@zentek.com
Kennyjo
2 년 전
Zentek Provides Update on Icephobic Coating Technology
Guelph, ON
September 19, 2022, Zentek Ltd. (“Zentek” or the “Company”) (Nasdaq: ZTEK; TSX-V: ZEN), an intellectual property development and commercialization company, has successfully completed sand erosion testing at the National Research Council (“NRC”) in Ottawa and rain erosion testing at the Anti-icing Materials International Laboratory (“AMIL”) in Quebec on Zentek’s patent-pending Icephobic Coatings. These results, when taken with the strong performance under accelerated ageing announced March 14, 2022, demonstrate that the company’s icephobic technology is durable in adverse conditions for both wind turbine and drone industries, where Zentek is currently maintaining its focus.
Summary of overall results to date as reported by the NRC and AMIL:
As reported in November 2021, icephobicity tests at the NRC yielded strong and consistent results with an average shear stress of 20 kPa required to passively remove ice accretion (results under 100 kPa are considered to demonstrate low adhesion). Retesting a year later yielded the same results, demonstrating strong stability.
Flight tests in real-world icing conditions demonstrated good performance of Zentek’s coating, with results indicating retardation of ice accretion (icephobicity) and low adhesion to accreted ice.
1,000 hours of UV exposure, equivalent to two years of UV damage in Canada, slightly increased the ice adhesion properties to 43 kPa, which is still considered to be an effective coating in removing ice.
Sand erosion testing demonstrated medium to good performance at a high speed of 540 km/h.
Rain erosion testing at AMIL demonstrated good performance at 160 km/h and 320 km/h based on our interpretation, speeds at which the leading edge of wind turbines blade tips are exposed.
NRC drone testing demonstrated consistent results of maintaining control of rotor thrust in icing conditions while uncoated blades failed to maintain thrust in the same indoor controlled environment.
NRC is preparing for outdoor, real-world environment testing of drone rotor blades with Zentek’s icephobic coating this winter.
AMIL is testing the performance of Zentek’s coating on a small wind turbine in an indoor controlled environment.
“We are very happy with both the performance and durability test results for our icephobic coating and look forward to continued testing and demonstration of our technology,” said Greg Fenton, CEO of Zentek. “Ice accretion is a significant problem in the drone and wind turbine industries with few robust solutions currently available. We believe our patent-pending technology may be a new innovative approach to addressing a significant global need and look forward to continued discussions with drone and wind turbine market participants who see value in potentially more effective icephobic technologies.”
Zentek has filed a full patent application with the Patent Cooperation Treaty, the international patent office, on August 2nd, 2022, for Nanomaterial-Enhanced Elastomer for Passive Ice Accretion Prevention. The patent application will publish approximately 6 months from the date of filing, marking the beginning of the 12-month national phase for Zentek to apply directly in each country of interest.
About Zentek Ltd.
Zentek is an IP development and commercialization company focused on the research, development and commercialization of novel products using graphene and nanomaterials for use in the healthcare industry and beyond.
Zentek’s proprietary ZenGUARD™ coating is patent-pending and shown to have 99% antimicrobial activity, including against COVID-19, for use in PPE and potentially HVAC systems and other industries. Zentek's ZenGUARD™ production facility is located in Guelph, Ontario.
For further information:
Tyler Dunn
Tel: (306) 717-6745
Email: tdunn@zentek.com
To find out more about Zentek Ltd., please visit our website at www.Zentek.com. A copy of this news release and all material documents in respect of the Company may be obtained on ZEN’s SEDAR profile at http://www.sedar.com/.
Forward-Looking Statements
This news release contains forward-looking statements. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Although Zentek believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Zentek disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Kennyjo
2 년 전
September 15, 2022
Zentek Ltd. (“Zentek” or the “Company”) (Nasdaq: ZTEK; TSX-V:ZEN an intellectual property development and commercialization company, reports, further to its press release dated April 11, 2022, that it has received the final report from Phase 1 testing under its Innovation Solutions Canada (“ISC”) Testing Stream contract, which notes that all Phase 1 targets were met including: (i) a sufficient reduction in live airborne test organisms without modification to existing HVAC systems, (ii) no reduction in air flow rates, and (iii) no significant shedding of the ZenGUARD™ coating. ZenGUARD™-coated HVAC filters demonstrated a maximum improvement of 99% compared to equivalent MERV-rated uncoated filters using a bacteriophage (a SARS-COV-2 surrogate).
“The significant increase in filtration efficiency of pathogen-laden water droplets, without an impact to airflow rates, creates a potentially powerful solution in the HVAC space,” said Greg Fenton, CEO of Zentek. “Working with current systems, and not requiring additional energy or changes to existing equipment, our technology could be a simple and energy-efficient approach to providing cleaner air for indoor spaces and is highly supportive of current global indoor air quality initiatives.”
Phase 1 testing was conducted by CremCo Laboratories with assistance by the Aerospace Research Centre, a department of the National Research Council of Canada. Zentek is now in Phase 2 Testing at the National Research Council to demonstrate a reduction in live airborne surrogate contamination within a modular classroom environment, simulating a real-world environment. The Company will report results when completed and validated.
About Zentek Ltd.
Zentek is an IP development and commercialization company focused on the research, development and commercialization of novel products using graphene and nanomaterials for use in the healthcare industry and beyond.
Zentek’s proprietary ZenGUARD™ coating is patent-pending and shown to have 99% antimicrobial activity, including against COVID-19, for use in PPE and potentially HVAC systems and other industries. Zentek's ZenGUARD™ production facility is located in Guelph, Ontario.
For further information:
Tyler Dunn?
Tel: (306) 717-6745?
Email: tdunn@zentek.com
makinezmoney
3 년 전
$ZTEK: Opening up to 8.37 !!!!!!!!!!!
Biggggggggggggg move higher in PreMarket.........
Zentek Ltd., formerly ZEN Graphene Solutions Ltd., is a Canada-based intellectual property development and commercialization company. The Company is focused on next-gen healthcare solutions in the areas of prevention, detection, and treatment. The Company's technology helps filter and deactivate pathogens to reduce the risk of transmission. The Company is focused on commercializing ZenGUARD, which is a hydrophilic, water attracting coating that adsorbs bacteria and virus-laden aerosols and deactivates them, increasing public safety, and reducing the risk of transmission of COVID and other pathogens. The Company is developing a graphene-based fuel additive that can reduce greenhouse gas (GHG) emissions from diesel and bio-diesel fuels. It also intends to focus on commercializing few layers graphene and developing technology to produce monolayer graphene. The Company's manufacturing facility is located at 1123 York Rd, Guelph, Ontario.
$TMNA is next to do the same thing as it uplists from OTC to NYSE in APRIL 2022
GO $ZTEK
Kennyjo
3 년 전
I hate this short shit….
March 8, 2022
Zentek Ltd. (“ZEN” or the “Company”) (TSX-V:ZEN and OTC:ZENYF), a Canadian IP development and commercialization company focused on next-gen healthcare solutions has become aware of certain rumours and allegations being circulated, and categorically refutes the egregious allegation regarding the theft of intellectual property from Graphene Composites Ltd.
On January 29, 2021, the Company was served with a statement claim issued by Graphene Composites Ltd. and is in the process of defending the action, which it considers frivolous and without merit. The Company has considered the allegations as set out in the claim and, in light of the facts, the lack of clarity in the claim, and, based on discussions with the Company’s litigation counsel, the assessment of the merits of the claim and the defenses available to the Company, and the Company’s conclusion is that the risk of the Company suffering loss in respect of the claim is remote, and therefore the Company determined the claim not to be material or constituting ”significant litigation” pursuant to the policies of the TSX Venture Exchange. The Company continues to view this claim as frivolous and will continue to vigorously defend itself against these allegations.
The Company is aware of a 2,904,839 share Consolidated Short Position (less than 3% of total shares outstanding) in the marketplace as of March 1, 2022. Furthermore, the Company believes these false allegations were meant to hurt the Company’s credibility.
turnert
3 년 전
"Revenue stream of 100 mill? Try Gross Margin of 240 mill. That's already set up with the contracts to buy enough GO for 3 billion mask equivalents over 6 months. Do the math @ 4 cts a mask. (Zen gives a range of 3-6 cts a mask) The contract is a 6 billion annual run rate. 6 bill times 4 cts...... 240 mill Gross margin (not Rev, Gross margin) If we assume a 50% margin, Rev would be about 480 mill.... Market cap is therefore approx 1 times sales of masks/mask equiv line. Nothing yet said of the spit test contribution, which was said to be out 1st qtr. (another Line) Treatment silver/GO Line prob will take a year or more, but de-icer stuff, maybe a year. Then there is the Biggie.... fuel additive... 2-4 years??
chico237
3 년 전
Please see the following D.D. -Murocman
(The following from Johan/Yahoo board)
"A complete 180 pivot to R&D which turned very successful due to universities across Canada accruing interest in the Graphene derived from the Albany graphite. The resulting partnerships has allowed Zentek the opportunity to commercialize many IP developed in collaboration with their own researchers and experts across the country.
Now finalizing commercialization of the Anti-microbial compound which initialized a growing cult interest in the company. Those willing to put in the research do not have a hard time finding reasons to invest in what is turning into a burgeoning IP-spinoff company with primary focus on Healthcare.
Current commercial capacity suggests a procurement of around what is equivalent to material used to coat 9.6 billion masks, with ability to spread that production capacity into applications as they are approved, among which include:
Masks 1% of global >$200 mil/year, MASKS ALONE!
Gloves 1% of global >$50mil/year,
HVAC filters 1% of global >$150mil/year,
Medical Gowns, caps, booties,
Bedsheets,
High-touch surfaces,
Cardboard, paper, & other packaging material,
Bandages..
Much more
Compound also undergoing human trials next year for pharmaceuticals. Expected testing multiple skin conditions and gut infections. Early safety tests suggests this will be very safe with very high potency.
Further, the company expects to release a highly competitive rapid aptamer test for localized usage and results under 10 minutes. To be developed for everything from STD's to cancer. New aptamers are
expected to require an additional one to two months to be integrated within the pathogen detection
system
Will seek to develop:
(i) commercially synthesized aptamers for the detection of COVID-19;
(ii) aptamer deposition on screen printed electrodes;
(iii) an automated detector device that adds the fluidic buffers to the sensor and integrates a potentiostat which measures impedance indicating the presence of absence of the targeted pathogen; and
(iv) software that connects the detector to a device and management system.
A prototype of the system is expected to be completed in 2022, at which point a final commercialization strategy will be determined based on the market data. The Corporation then intends to request approval for the rapid test under the interim order provision at Health Canada.
As an IP development company, they are involved in many special projects:
• Ice-phobic coating, planes, pavement, power lines
• Anti-corrosive coating, heavy maritime potential
• Fuel additives, aerospace fuels, diesels and gasoline
• Concretes, small 0.02% graphene improves tensile and compressive strengths by >40-80%
• Batteries (mentioned recently by CEO but not much has been disclosed)
• 3D conductive filaments for a variety of applications,
• Graphene quantum dot synthesis and applications,
• Graphene synthesis, has secured patent rights for in-house production through Guelph University
• Upscaling recycled plastics,
• Magnetic filament fabrication,
According to information circular, any of these could justify another pilot plant scale application 2022.
As a results of being a graphite play, Zentek Ltd. retains ownership of the Albany deposit, of which is not priority but could be outsourced or sold to further pursue the intense future proofing that the IP could provide."
IMHO & Speculation this will be a $10 NASDAQ stock in 2022. Do your own D.D. & form your own conclusions
Chico
turnert
3 년 전
Hi guys and gals.... been a while. this board has been crickets for so long, I migrated to the SI board. Since things are picking up, I thought I'd stick my head in. IMO, the next 5 or 6 months are going to be EPIC. If looking for more Info, check out SI, CEO, or Reddit. Reddit seems to be better for navigating and finding real intel. SI's 2 zen boards are better for conversations. Back later.
Hot Features
프리미엄
실시간 알림, 사용자 정의 포트폴리오 및 시장 동향을 받으려면 등록하세요.
Monksdream
1 년 전
AJ Freely
1 년 전
TheFinalCD
3 년 전
Renee
3 년 전
nowwhat2
3 년 전
